To print: Select File and then Print from your browser's menu
---------------------------------------------------------------------------------------
Title: Ceftobiprole Approved in Canada for Treatment of Complicated Skin Infections
URL: http://www.pslgroup.com/dg/224AC2.htm
Doctor's Guide
June 30, 2008

BASEL, Switzerland -- June 30, 2008 -- Health Canada has authorised the marketing of ceftobiprole medocaril for injection (ZEFTERA) for the treatment of complicated skin and soft tissue infections including diabetic foot infections.

Ceftobiprole is the first approved broad-spectrum anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotic belonging to the cephalosporin class. It is specially designed to bind the penicillin-resistant targets in many Gram-positive bacteria of the cocci-type, resulting in bactericidal activity towards MRSA and penicillin-resistant Streptococcus pneumoniae.

Ceftobiprole as a single intravenous agent has demonstrated broad-spectrum activity against many other Gram-positive as well as Gram-negative bacteria, frequently associated with community and hospital-acquired infections.


SOURCE: Basilea Pharmaceutica Ltd.

---------------------------------------------------------------------------------------------
Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.
---------------------------------------------------------------------------------------------
This news story was printed from *Doctor's Guide to the Internet*
located at http://www.docguide.com
---------------------------------------------------------------------------------------

Return to News Story Page

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.
All contents Copyright (c) 1998 P\S\L Consulting Group Inc.
All rights reserved.